在脂蛋白中新兴的药理学策略 (a) 降低
Taha Mansoor1, Mahmoud Ismayl2, Sachin Parikh3
1Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA.
概括
升高的脂蛋白 (Lp) 是心血管疾病的风险. 未来的试验将确定是否通过药物降低Lp(a) 降低心血管事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 脂蛋白 (Lp) 是一种类似于LDL的粒子.
- 升高的Lp (a) 是动脉样硬化心血管疾病 (ASCVD) 和动脉狭窄症的因果风险因素.
- 目前没有任何试验表明Lp(a) 降低是否降低ASCVD风险,同时控制最佳的LDL胆固醇.
研究的目的:
- 总结正在进行的临床试验,调查向的Lp (a) 降低药物治疗.
- 确定评估心血管终点的大规模结局试验.
主要方法:
- 搜索了clinicaltrials.gov,从2025年5月起进行相关研究.
- 包括十二项符合标准的临床研究.
- 专注于第二期和第三期试验,包括三个主要的第三期结论试验.
主要成果:
- 三个主要的第三期结局试验 (Lp(a) HORIZON,OCEAN(a),ACCLAIM-Lpa(a)) 正在评估佩拉卡森,奥尔帕西兰和莱波迪西兰.
- 这些试验评估主要不良心脏事件 (MACE) 终点.
- 其他2期和3期试验也在进行中.
结论:
- 预计即将公布的试验结果将澄清Lp(a) 减少对心血管临床结果的影响.
- 结果将决定是否有针对性的Lp(a) 降低可以改善患者的预后.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Angina IV: Management
22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Atherosclerosis I: Introduction
77
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77


